1. Future Offspring Costs in Economic Evaluation

   • Evelyn Verbeke
   • Jeroen Luyten

   Current Opinion 29 October 2021 Pages: 141 - 147

   

2. Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency

   • Gemma E. Shields
   • Mark Wilberforce
   • Linda M. Davies

   Practical Application 29 October 2021 Pages: 149 - 156

   

3. How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents

   • Cate Bailey
   • Kim Dalziel
   • The Quality Of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team

   Review Article Open access 05 November 2021 Pages: 157 - 182

   

4. Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review

   • Thitima Kongnakorn
   • Grammati Sarri
   • Xinke Zhang

   Systematic Review Open access 01 October 2021 Pages: 183 - 201

   

5. The Utility of a Rapid Review Evaluation Process to a National HTA Agency

   • Áine Varley
   • Lesley Tilson
   • Michael Barry

   Original Research Article Open access 12 October 2021 Pages: 203 - 214

   

6. The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions

   • Yan Meng
   • Philip M. Clarke
   • Ilias Goranitis

   Original Research Article 21 October 2021 Pages: 215 - 223

   

7. Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?

   • James D. Chambers
   • Nikoletta M. Margaretos
   • Xin Ye

   Original Research Article 26 October 2021 Pages: 225 - 232

8. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS

   • Megan Perry-Duxbury
   • James Lomas
   • Pieter van Baal

   Original Research Article Open access 26 October 2021 Pages: 233 - 239